The cholinergic REM sleep induction test with pilocarpine in mildly depressed patients and normal controls.
Publication/Presentation Date
1-1-1993
Abstract
Previous studies suggested that depressed patients enter rapid-eye movement (REM) sleep more quickly than normal controls following the administration of muscarinic agonists such as arecoline or RS 86. We recently reported that pilocarpine, an orally active muscarinic agonist, induced REM sleep and reduced Stage 3 & 4 (Delta) sleep in young normal volunteers. In this study we present preliminary evidence that pilocarpine had similar effects on REM latency, REM percentage, and Delta (Stages 3 & 4) sleep percentage in depressed patients and controls. Pilocarpine, however, decreased stage-4 sleep in controls more than in depressed patients. Because this group of patients were only mildly depressed at the time of the study, had a high frequency of comorbid substance abuse diagnoses, and had normal electroencephalogram (EEG) sleep patterns under placebo conditions, further studies are necessary to test the hypothesis that depressed patients show hypersensitive cholinergic REM sleep induction.
Volume
33
Issue
1
First Page
33
Last Page
39
ISSN
0006-3223
Published In/Presented At
Lauriello, J., Kenny, W. M., Sutton, L., Golshan, S., Ruiz, C., Kelsoe, J., Rapaport, M., & Gillin, J. C. (1993). The cholinergic REM sleep induction test with pilocarpine in mildly depressed patients and normal controls. Biological psychiatry, 33(1), 33–39. https://doi.org/10.1016/0006-3223(93)90275-i
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
8420594
Department(s)
Administration and Leadership
Document Type
Article